FDA approves Opdivo in RCC

FDA approved Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The approval came well in advance of the drug's March 16, 2016, PDUFA date. ...